BELITE BIO INC - AMERICAN DEPOSITARY SHARES

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

17 Mar 2025 06:00:34 By Nasdaq GlobeNewswire

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

17 Mar 2025 06:00:02 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

11 Mar 2025 03:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

04 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

27 Feb 2025 02:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Registered Direct Offering of $15 Million

05 Feb 2025 22:35:00 By Nasdaq GlobeNewswire

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

12 Nov 2024 01:00:25 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

03 Nov 2024 16:00:27 By Nasdaq GlobeNewswire

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

14 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

08 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

10 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in Three Upcoming Investor Conferences

03 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

01 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

09 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

08 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

05 Aug 2024 19:10:54 By Nasdaq GlobeNewswire

Belite Bio to Present at the JonesHealthcare Seaside Summit

08 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

12 Jun 2024 02:55:28 By Nasdaq GlobeNewswire

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference

14 May 2024 08:00:00 By Nasdaq GlobeNewswire